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Abstract
Introduction: Mutations	 in	 the	angiogenin	 (ANG)	 gene	are	known	 to	be	associated	
with	both	familial	and	sporadic	amyotrophic	lateral	sclerosis	(ALS).	The	majority	of	
disease‐causing	mutations	of	ANG	result	in	loss	of	either	ribonucleolytic	activity,	nu‐
clear translocation activity or both.
Methods: We sequenced ANG	gene	from	a	total	of	136	sporadic	ALS	patients	and	
112 healthy controls of Hungarian origin. To elucidate the role of the R33W mutation 
in	the	disease	mechanism,	computational,	and	functional	analyses	were	performed.
Results: Mutation	screening	revealed	a	mutation	located	in	the	signal	peptide	(M‐24I)	
and	two	mutations	that	affect	the	mature	protein	(R33W,	V103I).	The	R33W	muta‐
tion,	which	has	not	been	previously	detected	in	ALS	patients,	affects	the	key	amino	
acid	of	the	nuclear	translocation	signal	of	the	ANG	protein.	Molecular	dynamics	sim‐
ulations suggested that the R33W mutation results in partial loss of ribonucleolytic 
activity and reduced nuclear translocation activity. The ribonucleolytic assay and nu‐
clear	translocation	assay	of	the	R33W	ANG	protein	confirmed	the	molecular	dynam‐
ics results.
Conclusions: In	the	Hungarian	ALS	population,	the	observed	frequency	of	ANG mu‐
tations	was	2.9%,	which	is	higher	than	previously	reported	for	sporadic	cohorts.	The	
evidence from computational and functional analyses support the deleterious effect 
of the novel R33W variant detected in this study.
K E Y W O R D S
amyotrophic	lateral	sclerosis,	angiogenin,	molecular	dynamics,	mutation	screening,	nuclear	
translocation,	ribonucleolytic	activity
1  | INTRODUC TION
Amyotrophic	lateral	sclerosis	(ALS)	is	a	fatal	neurodegenerative	dis‐
ease	characterized	by	the	loss	of	motor	neurons	leading	to	paralysis	
and	death	3–5	years	after	disease	onset.	Approximately	90%–95%	
of	 cases	 are	 sporadic	 with	 no	 family	 history	 (sALS),	 whereas	 the	
remaining	 5%–10%	 is	 familial	 (fALS;	 Renton,	 Chiò,	 &	 Traynor,	
2014);	 however,	 the	 clinical	 features	of	 fALS	and	 sALS	are	 almost	
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indistinguishable.	In	the	past	decades,	more	than	30	genes	involved	
in	 the	 etiology	 of	 the	 disease	 have	 been	 identified	 (Amyotrophic	
Lateral	 Sclerosis	Online	Genetics	 Database,	 ALSoD;	 Abel,	 Powell,	
Andersen,	 &	 Al‐Chalabi,	 2012).	 The	 prevalence	 of	 mutations	 of	
the	two	most	frequently	mutated	genes,	SOD1 and C9orf72 repeat 
expansion	 was	 previously	 reported	 for	 the	 Hungarian	 population	
(Tripolszki	et	al.,	2017).
First	 reported	 in	 2004,	 substantial	 evidence	 has	 accumulated	
for angiogenin	 (ANG)	 involvement	 in	 ALS	 (Greenway	 et	 al.,	 2004;	
Sheng	&	Xu,	2016).	To	date,	approximately	30	different	mutations	
are reported for ANG	 in	 the	 ALSoD	 (Abel	 et	 al.,	 2012).	 The	ANG 
gene,	 located	on	chromosome	14q11.2,	encodes	ANG,	a	123‐resi‐
due,	14.1‐kDa	protein.	The	ANG	protein	belongs	to	the	pancreatic	
ribonuclease	superfamily	(Strydom	et	al.,	1985),	and	it	plays	an	im‐
portant	role	in	rRNA	biogenesis	and	cellular	proliferation	(Kishimoto,	
Liu,	Tsuji,	Olson,	&	Hu,	2005)	in	addition	to	its	crucial	role	in	inhib‐
iting	 protein	 translation	 by	 cleaving	 transfer	 RNA	 (tRNA;	 Ivanov,	
Emara,	Villen,	Gygi,	&	Anderson,	2011).	ANG	is	synthesized	with	a	
signal peptide of 24 amino acids that is cleaved to form the mature 
protein	 (Fett	 et	 al.,	 1985;	 Shapiro,	 Riordan,	 &	 Vallee,	 1986).	 The	
mature protein contains three functional sites: a receptor binding 
region 60NKNGNPHREN68,	 the	 catalytic	 triad	 His13,	 Lys40,	 and	
His114,	which	is	responsible	for	ribonuclease	activity,	and	a	nuclear	
localization	signal	sequence	29IMRRRGL35,	which	is	responsible	for	
translocation	into	the	nucleus	(Figure	1;	Hallahan,	Shapiro,	Strydom,	
&	Vallee,	1992;	Leonidas	et	al.,	1999;	Moroianu	&	Riordan,	1994).	It	is	
known	that	ANG	mediates	neurovascularization	and	promotes	neu‐
rite outgrowth during early embryonic development and that it pro‐
tects	against	hypoxia‐induced	motor	neuron	death	(Kishimoto	et	al.,	
2005;	Moroianu	&	Riordan,	1994;	Sebastià	et	al.,	2009).	Mutations	in	
the ANG gene cause loss of either ribonucleolytic activity or nuclear 
translocation	activity	or	both	(Wu	et	al.,	2007).
The aim of this study was to evaluate the contribution of muta‐
tions in ANG,	a	major	ALS	gene,	to	the	pathogenesis	of	the	disease	
in Hungarian patients. The patients positive for SOD1 or C9orf72 
repeat	expansion	 identified	 in	our	previous	study	 (Tripolszki	et	al.,	
2017)	were	not	excluded,	as	there	is	evidence	that	ALS	is	oligogenic	
(van	Blitterswijk	et	al.,	2012).	To	explore	the	underlying	mechanisms	
F I G U R E  1   The R33W mutation identified in the angiogenin	(ANG)	gene	in	a	Hungarian	sporadic	amyotrophic	lateral	sclerosis	patient.	
(a)	Electropherograms	of	wild‐type	and	mutant	ANG	sequences.	(b)	X‐ray	structure	of	human	ANG	in	cartoon	representation	showing	
its	functional	sites	and	R33W	mutation.	Cartoon	representation	of	the	structure	of	human	ANG	(Protein	Data	Bank:	1B1I)	showing	its	
functional	sites:	catalytic	triad	residues	His13,	Lys40,	and	His114	are	shown	as	stick	models;	nuclear	localization	signal	is	shown	in	cyan;	
and	receptor	binding	sites	are	shown	in	green.	The	R33W	mutation	is	represented	as	stick	model	in	yellow.	(c)	Alignment	of	ANG	protein	
sequences from various species shows the conservation of the R33 residue
(a) (b)
(c)
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that result in loss of function of the detected R33W mutant pro‐
tein,	computational	simulations,	ribonucleolytic	assays,	and	nuclear	
translocation assays were performed.
2  | PATIENTS AND METHODS
2.1 | Patients
The	 investigated	sporadic	patients	 (n	=	136)	were	 recruited	 from	
the	 Department	 of	 Neurology,	 University	 of	 Szeged,	 Szeged,	
Hungary.	All	patients	fulfilled	the	revised	El	Escorial	criteria	for	ALS	
(Ludolph	et	al.,	2015).	Among	the	patients,	54	were	males	and	82	
were	females	(M/F	ratio	was	1:1.51),	and	the	mean	age	of	disease	
onset	was	 60.72	 years	 (range	 29–86	 years).	 All	 patients	were	 of	
Hungarian	ancestry.	The	study	was	approved	by	the	Internal	Ethical	
Review	Board	of	the	University	of	Szeged.	Written	informed	con‐
sent	was	obtained	from	all	patients,	and	the	study	was	conducted	
according to the Principles of the Declaration of Helsinki.
2.2 | Methods
2.2.1 | Genetic analysis
Genomic	DNA	was	 isolated	 from	 frozen	 blood	 using	DNeasy	Blood	
and	Tissue	kit	(QIAGEN,	Gödöllő,	Hungary).	The	coding	region	and	the	
flanking introns of the ANG	gene	were	amplified	(primer	sequences	used	
were	taken	from	Fernández‐Santiago	et	al.,	2009).	Direct	sequencing	of	
the	PCR	products	was	performed	on	an	ABI	3100	sequencer	and	com‐
pared	with	the	reference	gene	sequences	(ANG,	RefSeq	NM_001145).	
To	 identify	known	variations,	ALSoD	(http://alsod.iop.kcl.ac.uk/,	Abel	
et	 al.,	 2012),	 1,000	 Genomes	 Database	 (www.1000g	enomes.org/),	
dbSNP	(http://www.ncbi.nlm.nih.gov/proje	ct/SNP),	and	gnomAD	(Lek	
et	al.,	2016)	databases	were	used.	To	predict	the	functional	effects	of	
mutations,	the	combination	of	seven	variant	prioritization	tools	avail‐
able	 from	 the	 dbNSFP	 database	 v3.0	 (MetaSVM,	 MetaLR,	 CADD,	
PROVEAN,	 SIFT,	MutationTaster,	MutationAssessor)	were	 used	 (Liu,	
Wu,	Li,	&	Boerwinkle,	2016).	Amino	acid	numbering	of	ANG	is	accord‐
ing	to	the	ALS	Online	Database	(Abel	et	al.,	2012),	which	has	been	used	
in the previous published reports on ANG mutations.
2.2.2 | System setup and all‐atom molecular 
dynamics simulations
The	crystal	structure	of	 the	human	ANG	protein	 (entry:	1B1I)	was	
retrieved	from	the	RCSB	Protein	Data	Bank	and	used	as	the	starting	
structure	(Leonidas	et	al.,	1999).	The	R33W	variant	identified	in	the	
Hungarian	patient	was	modeled	in	silico	by	mutating	Arg33	residue	
to	Trp33,	while	keeping	the	secondary	structure	intact.	The	cofac‐
tor,	CIT	and	crystallographic	waters	were	removed	from	the	struc‐
ture	and	hydrogen	atoms	were	added	subsequently	using	the	Xleap	
tool	 of	AMBER	14	 (Case	et	 al.,	 2014).	Modeled	 structures	 for	 the	
wild‐type	and	R33W	proteins	were	then	solvated	 in	an	octahedral	
box	of	TIP3P	water	with	~10	Å	between	the	protein	surface	and	the	
box	boundary	(Jorgensen,	Chandrasekhar,	Madura,	Impey,	&	Klein,	
1983).	Each	system	was	then	electrostatically	neutralized	by	the	ad‐
dition of Cl− counter ions and simulations were carried out using the 
SANDER	module	of	 the	AMBER	14	software	package	with	ff14SB	
force	field	(Maier	et	al.,	2015).
Generation	 of	 topology	 and	 parameter	 files,	 energy	minimiza‐
tion,	heating	and	temperature	equilibration,	production	run,	and	MD	
trajectory	analysis	was	carried	out	as	described	previously	 (Padhi,	
Banerjee,	Gomes,	&	Banerjee,	2014;	Padhi	&	Gomes,	2019;	Padhi,	
Kumar,	Vasaikar,	Jayaram,	&	Gomes,	2012).	All	figures	for	represent‐
ing	ANG	structures	were	generated	using	PyMOL	and	visual	molec‐
ular	dynamics	(VMD).	A	VMD	plug‐in,	VolArea,	was	used	to	calculate	
the	 solvent‐accessible	 surface	 area	 (SASA)	 of	 nuclear	 localization	
signal residues 31RRR33	using	a	probe	radis	of	1.4	Å	for	evaluating	the	
nuclear	translocation	activity	(Humphrey,	Dalke,	&	Schulten,	1996;	
Ribeiro,	Tamames,	Cerqueira,	Fernandes,	&	Ramos,	2013).
2.2.3 | Solvent‐accessible surface area
The	nuclear	 translocation	activity	of	 the	R33W	variant	was	exam‐
ined	by	computing	the	SASA	of	nuclear	localization	signal	residues	
31RRR33.	A	VMD	plug‐in,	VolArea,	was	used	to	calculate	the	SASA	of	
wild‐type	and	R33W	using	a	probe	radius	of	1.4	Å	(Humphrey	et	al.,	
1996;	Ribeiro	et	al.,	2013).
2.2.4 | Graphics and figure preparation
All	 figures	 for	 representing	ANG	 structures	were	 generated	using	
PyMOL	(http://www.pymol.org)	and	VMD.	Hydrogen	bond	interac‐
tions	were	visualized	using	Cytoscape	(Shannon	et	al.,	2003).
2.2.5 | Ribonucleolytic activity assay
The	 ribonucleolytic	 activity	 of	 the	 wild‐type	 and	 mutant	 ANG	
protein was determined by measuring their activity toward yeast 
tRNA	 (Shapiro	 et	 al.,	 1986).	 The	 30	 μl	 assay	 mixtures	 contained	
0.05–0.4	mg/ml	wild‐type	 or	 R33W	mutant	 ANG	 (14.3	 kDa)	with	
>95%	 purity	 (Novoprotein	 Scientific,	 Summit,	 NJ),	 30	 mM	 4‐(2‐
hydroxyethyl)‐1‐piperazineethane‐sulfonic	 acid,	 pH	 6.8	 (Sigma),	
30	mM	sodium	chloride	(Sigma),	3	μg	ultrapure	RNAse‐free	bovine	
serum	albumin	(BSA,	Thermo	Fisher),	and	60	μg	yeast	tRNA	(Sigma).	
After	2	hr	of	 incubation	at	37°C,	70	μl	of	3.4%	 ice‐cold	perchloric	
acid	 (Sigma)	was	added	to	terminate	the	reaction.	After	vortexing,	
the	mixtures	were	 incubated	on	 ice	for	15	min,	and	centrifuged	at	
15,000 g	for	10	min	at	4°C.	Supernatant	absorbance	was	measured	
at	260	nm	with	a	MaestroNano	spectrophotometer.	Data	were	col‐
lected	from	three	independent	experiments.
2.2.6 | Nuclear translocation assay
Human	umbilical	vein	endothelial	cells	(HUVEC;	Cell	Applications	Inc.,	
San	Diego,	CA)	were	grown	in	Endothelial	Cell	Growth	Medium	(Cell	
Applications)	in	a	humidified	atmosphere	with	5%	CO2	at	37°C.	Cells	
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were seeded at 5 × 105	cells/ml	onto	an	eight‐well	cell	culture	slide	
(Biologix,	Shandong,	China)	and	incubated	with	1	μg/ml	of	wild‐type	
or	mutated	 (R33W)	ANG	protein	 (recombinant	 proteins	 contain	N‐
terminal	methionine,	Novoprotein	Scientific,	Summit,	NJ)	for	30	min	
at	37°C.	Cells	were	fixed	with	4%	paraformaldehyde	(Sigma	Aldrich	
Ltd.,	Budapest,	Hungary)	and	permeabilized	with	0.25%	Triton	X‐100	
(Sigma	Aldrich	Ltd.).	Nonspecific	binding	was	prevented	by	incubation	
in	1%	BSA	and	1%	normal	goat	serum	(Sigma	Aldrich	Ltd.)	followed	by	
incubation	with	an	anti‐ANG	mouse	monoclonal	antibody	[14,017.7]	
(Abcam,	Cambridge,	UK)	overnight	at	4°C	and	Alexa	Fluor	647	anti‐
mouse	IgG	(Sigma	Aldrich	Ltd.)	for	90	min	at	room	temperature.	The	
nuclei	were	counterstained	with	4′,6‐diamidino‐2‐phenylindole	dihy‐
drochloride	(Sigma	Aldrich	Ltd.).	Slides	were	mounted	by	Fluoromount	
(Emergo	 Europe,	 Hague,	 Netherlands)	 and	 visualized	 using	 a	 Zeiss	
LSM	880	Laser	Scanning	Microscope	fitted	with	PMT	and	GaASP	de‐
tectors	(Carl	Zeiss	Microscopy	GmbH,	Jena,	Germany).	 ImageJ	soft‐
ware	(Ver.	1.52)	was	used	to	determine	mean	signal	intensity	of	each	
cell and the cytoplasm and nucleus of each cell in at least three fields 
of	view	per	experiment	and	condition	(Schneider,	Rasband,	&	Eliceiri,	
2012).	The	ratio	of	nuclear/whole	staining	intensity	was	calculated	to	
determine	nuclear	localization	intensity	of	ANG,	two‐tailed	T‐test	was	
used to determine significance with a significance level set at p	≤	0.05.
3  | RESULTS
Mutation	analysis	of	the	ANG	gene	revealed	three	coding‐region	mu‐
tations	in	four	ALS	patients	(4/136	patients;	2.94%).	One	of	the	de‐
tected	mutations	affects	the	signal	peptide	(M‐24I)	and	the	two	are	
located	in	the	mature	ANG	protein	(R33W,	V103I).	These	mutations	
were	not	detected	in	112	age‐matched	healthy	controls.
ANG	sequence	analysis	confirmed	the	presence	of	the	rs11701	
polymorphism	in	our	ALS	and	control	populations.	We	did	not	ob‐
serve	 significant	 differences	 in	 allelic	 distributions	 between	 sALS	
patients,	 (minor	 allele	 frequency,	 MAF(G)	 =	 0.118)	 and	 controls	
(MAF(G)	=	0.171).
3.1 | M‐24I mutation
The	known	M‐24I	mutation	(c.3G>T)	was	detected	in	two	patients.	
One	 of	 the	 patients,	 who	 was	 described	 in	 our	 previous	 study	
(Tripolszki	 et	 al.,	 2017),	 also	 carried	 a	mutation	 in	 the	SOD1 gene 
(V14M).
Clinical report: The other patient with the ANG	M‐24I	mutation	
was	a	79‐year‐old	woman.	Her	symptoms	started	6	months	before	
the	examination	with	progressing	dysphagia	and	dysarthria.	On	ex‐
amination she was anarthric with increased gag and soft palate re‐
flex	and	exhibited	difficulty	moving	the	tongue,	which	showed	slight	
muscle	atrophy.	Deep	tendon	reflexes	were	increased	in	the	extrem‐
ities;	however,	she	did	not	complain	of	weakness,	even	though	signs	
of lower motor neuron damage were detected with electromyog‐
raphy	 (EMG).	The	revised	ALS	Functional	Rating	Scale	 (ALSFRS‐R)	
was	33	(the	normal	score	is	48).	The	Mini‐Mental	State	Examination	
(MMSE)	score	was	 in	 the	normal	 range:	27	 (the	maximum	score	 is	
30).	The	patient	could	communicate	in	writing.	The	initial	symptoms	
indicated pseudobulbar palsy.
3.2 | V103I mutation
A	recurrent	missense	variant	(c.379G>A;	V103I)	was	identified	in	the	
mature	ANG	protein.
Clinical	report:	The	patient	with	the	V103I	mutation	was	a	63‐
year‐old	 man	 presenting	 with	 severe	 weakness	 of	 the	 right	 arm	
due	 to	muscle	 atrophy.	 Slight	 bulbar	 and	 pseudobulbar	 weakness	
was	noted,	and	the	muscle	strength	also	diminished	in	his	 left	arm	
without	severe	atrophy	of	the	muscles.	The	lower	extremities	were	
relatively	 strong.	 The	 patient	 could	 walk	 normally.	 Nevertheless,	
fasciculations	were	 seen	 in	 all	 the	muscles	 of	 the	 extremities	 and	
observed together with fibrillations and positive sharp waves on 
EMG	examination,	which	are	 indicative	of	 lower	motor	neuron	 le‐
sions.	The	ALSFRS‐R	was	41.	The	disease	 started	1.5	year	before	
the	examination.	He	was	operated	with	coarctation	of	the	aorta	and	
an	artificial	valve	was	implanted	15	years	before	the	onset	of	ALS.	
He	was	on	continuous	Coumadin	treatment.	The	result	of	the	MMSE	
was 28 and was comparable with the global impression that the pa‐
tient had no intellectual deficit. The initial disease sign was lower 
motor neuron damage of the right arm.
3.3 | R33W mutation
A	missense	variant	(c.169C>T;	R33W)	located	in	the	nuclear	localiza‐
tion	signal	was	identified	in	one	patient	(Figure	1).	This	variant	has	
not	been	previously	reported	in	an	ALS	patient,	but	occurs	with	a	low	
allele	frequency	 in	the	gnomAD	database	(MAF(T)	=	0.00001624).	
Six	of	the	seven	computational	variant‐effect	prediction	tools	used	
predicted R33W to be pathogenic.
3.3.1 | Molecular dynamics simulations
MD	 simulation	 of	 the	 R33W	 variant	 protein	 was	 carried	 out	 to	
model structural and dynamics changes in the functional sites 
compared	 to	 the	 wild‐type	 protein.	 The	 backbone	 root	 mean	
square	deviation	(RMSD)	of	the	R33W	variant	obtained	from	MD	
simulations	 showed	 that,	 although	 the	 fluctuations	 were	 higher	
than	the	wild‐type	during	the	first	15	ns,	it	subsequently	stabilized	
and	converged	as	observed	in	the	wild‐type	ANG	(Figure	S1).	This	
suggested	 that	 the	Arg33	 to	Trp33	mutation	may	not	 affect	 the	
structural stability of the mutant.
3.3.2 | Conformational switching of catalytic 
residue His114 causes loss of ribonucleolytic function 
in the R33W protein
MD	 simulations	 were	 carried	 out	 to	 examine	 whether	 the	 R33W	 
variant	exhibits	a	 loss	of	 ribonucleolytic	activity.	A	100	ns	all‐atom	
simulation of the R33W variant protein revealed that one of the 
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catalytic	 residues,	 His114,	 exhibited	 a	 characteristic	 conformational	
switching	from	its	native	position	during	the	simulations	(Figure	2A).	
As	 established	 in	 our	 previous	 studies	 (Padhi,	 Jayaram,	 &	 Gomes,	
2013;	Padhi,	Vasaikar,	Jayaram,	&	Gomes,	2013;	Padhi	et	al.,	2014),	this	
conformational switching of His114 results in loss of ribonucleolytic 
activity.	The	R33W	variant	showed	a	similar	behavior,	where	the	quan‐
titative	HA‐CA‐CB‐CG	dihedral	angle	measurement	of	His114	deviated	
from	the	mean	−80°	position	to	−179°	(Figure	2B).	Thus,	based	on	the	
MD	simulations	of	the	wild‐type	and	R33W	variant,	we	predict	that	the	
R33W variant is possibly reduces ribonucleolytic activity.
To	validate	 the	simulation‐based	prediction,	we	performed	the	
ribonucleolytic	assay	using	yeast	tRNA	as	substrate	and	our	quanti‐
tative	analysis	showed	that	the	R33W	mutant	retained	only	57.4%	of	
the	ribonucleolytic	activity	compared	to	wild‐type	ANG	(considered	
F I G U R E  2  Conformational	switching	of	catalytic	residue	His114	in	R33W	mutant.	(A)	Snapshots	extracted	from	molecular	dynamics	
(MD)	simulation	of	wild‐type	angiogenin	(ANG)	(a	and	b)	showing	the	native	and	stable	conformation	of	catalytic	residue	His114	as	compared	
to	the	conformational	altered	His114	switching	in	R33W	mutant	(c	and	d)	as	observed	during	the	MD	simulation.	(B)	Change	in	HA‐CA‐CB‐
CG	dihedral	angle	of	catalytic	residue	His114	during	MD	simulation	as	a	function	of	time.	Catalytic	residue	His114	changed	its	conformation	
from	native	−80º	during	the	simulations,	indicating	its	role	in	probable	loss	of	ribonucleolytic	activity,	whereas	wild‐type	ANG	maintained	a	
stable His114 conformation
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100%)	(Figure	3).	The	result	of	this	enzymatic	activity	assay	was	con‐
sistent	with	the	MD	simulation	results.
3.3.3 | Local folding of nuclear localization signal 
abolishes nuclear translocation activity of the 
R33W variant
The nuclear translocation activity of the R33W variant was in‐
vestigated	 from	MD	 simulations.	Our	 100	 ns	 simulation	 of	 R33W	
variant	 showed	 that	 the	 key	 nuclear	 localization	 signal	 residues	
31RRW33 undergo local folding and becomes less accessible to 
solvent	as	compared	to	wild‐type	(Figure	4A).	This	resulted	in	a	re‐
duced	SASA	in	the	R33W	variant	compared	to	the	wild‐type,	which	
retained an open conformation and loosely packed 31RRR33 resi‐
dues	(Figure	4B).	Since	the	31RRR33	residues	are	known	to	play	a	
pivotal	role	in	the	nuclear	translocation	of	ANG,	we	predicted	that	
a	 decrease	 in	 SASA	 due	 to	 the	 local	 folding	 and	 close	 packing	 of	
31RRR33 residues originated due to the replacement of hydrophilic 
Arg33	to	hydrophobic	Trp33	would	probably	lead	to	the	loss	of	nu‐
clear	translocation	activity	in	R33W	variant.	Our	MD	simulated	re‐
sults were verified through nuclear translocation assay performed 
on	 cultured	 HUVEC	 cells.	 Treatment	 with	 wild‐type	 and	 mutant	
R33W protein and subsequent immunofluorescent staining dem‐
onstrated	that	while	wild‐type	ANG	translocated	 into	the	nucleus,	
the	R33W	mutant	 remained	primarily	 in	 the	cytoplasm	 (Figure	5a,	
for	isotype	staining	see	Figure	S3).	Cells	with	nuclear	or	cytoplasmic	
staining	were	counted	and	while	wild‐type	ANG	showed	nuclear/cy‐
toplasmic	staining	in	24/34	cells	per	field	of	view,	the	R33W	mutant	
showed	nuclear/cytoplasmic	staining	in	14/37	cells	per	field	of	view	
on	average	(p	=	0.001,	determined	by	chi‐square	test,	the	chi‐square	
statistic	is	10.6984).	Decreased	translocation	of	R33W	ANG	into	the	
nucleus was also confirmed by quantification of nuclear/signal in‐
tensity	 (Figure	5b).	Besides	 the	difference	 in	nuclear	 translocation	
activity,	whole	cellular	staining	intensity	was	decreased	in	the	R33W	
ANG‐treated	 samples	 compared	 to	 the	WT	ANG‐treated	 samples	
(Figure	5c),	 suggesting	a	defect	 in	 the	cellular	 recognition	process	
and	 internalization	of	 the	mutant	 protein.	Untreated	HUVEC	 cells	
showed	no	staining	for	ANG	(Figure	S3a).
Clinical	 report:	 The	R33W	variant	was	 carried	by	 a	55‐year‐old	
male patient presented to our clinic with severe distally dominant at‐
rophy of the muscles in the arms with weakness. He noticed the initial 
symptoms	 1	 year	 before	 examination.	 A	 gradually	worsening	 diffi‐
culty of swallowing developed about half year after the initial symp‐
toms. The tongue was atrophic and the articulation was compromised. 
He	lost	25	kg	weight	since	symptom	onset.	On	physical	and	on	EMG	
examinations,	frequent	fasciculations	and	fibrillations	were	observed	
in	 all	 examined	myotomes,	 even	 in	 the	 lower	extremities.	The	gag‐	
and	soft	palate	reflexes	were	absent,	and	no	deep	tendon	reflexes	in	
the	upper	extremities	could	be	elicited.	However,	reflexes	were	exag‐
gerated	in	the	lower	extremities.	The	patient	could	walk	well	but	his	
arms were useless. He had been treated for depression in the previous 
2	years.	The	ALSFRS‐R	was	35.	The	MMSE	could	not	be	performed	
because of the patient's compromised speech and severe weakness of 
the	hands.	Nevertheless,	there	were	no	signs	of	mental	deterioration.
4  | DISCUSSION
In	this	study,	we	identified	three	mutations	in	the	coding	region	of	
the ANG	gene,	one	of	which	has	not	been	reported	previously	in	ALS	
patients. The frequency of ANG	mutations	 in	our	Hungarian	 sALS	
cohort	(4/136;	2.9%)	is	higher	than	previously	reported.	According	
F I G U R E  3  Ribonucleolytic	assay	of	wild‐type	(WT)	and	mutant	(MUT)	R33W	angiogenin	(ANG)	proteins.	Enzyme	activity	was	measured	
using	yeast	tRNA	as	substrate.	Increasing	concentrations	(0.05–0.4	mg/ml)	of	WT	and	R33W	(MUT)	proteins	were	incubated	with	yeast	
tRNA	(2	mg/ml)	at	37°C	for	2	hr.	Undigested	tRNA	was	precipitated	with	perchloric	acid.	The	absorbance	of	the	supernatants	was	measured	
at	260	nm.	Data	were	collected	from	three	independent	measurements.	Relative	enzyme	activity	of	the	MUT	ANG	was	calculated	as	
compared	with	the	WT	protein	(100%).	The	activity	differences	at	concentrations	0.1,	0.2,	0.3,	and	0.4	mg/ml	were	calculated
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to	previous	studies,	the	frequency	of	ANG mutations in patients with 
no	known	 family	history	 is	0.7%,	with	higher	 frequencies	 in	 some	
populations	(e.g.,	1.4%	and	1.9%	in	patients	of	Irish	or	Scottish	origin,	
respectively,	Greenway	et	al.,	2004,	2006)	and	2.4%	in	patients	with	
positive	family	history	(van	Es	et	al.,	2011).
4.1 | M‐24I mutation
The	M‐24I	mutation	was	first	described	by	Conforti	et	al.	(2008)	and	
was detected in two Hungarian patients in this study. The biological 
function of the signal peptide is not entirely understood; hence it is 
difficult	to	predict	the	effect	of	the	M‐24I	mutation.	Nonetheless,	it	
affects	the	start	codon	(ATG)	of	the	gene,	which	may	influence	the	
correct translation of the protein.
One of the patients with the ANG	M‐24I	also	carried	a	mutation	
in the SOD1	gene	(V14M)	and	was	described	in	our	previous	study	
(Tripolszki	et	 al.,	2017).	The	co‐occurrence	of	different	variants	 in	
ALS‐associated	genes	was	also	detected	in	other	ALS	cohort	screen‐
ings	(Kenna	et	al.,	2013;	Krüger	et	al.,	2016).
4.2 | V103I mutation
The	 V103I	 mutation	 affects	 an	 amino	 acid	 that	 is	 conserved	 in	
mammals	 and	 it	 was	 first	 detected	 in	 an	 ALS	 cohort	 of	 Chinese	
F I G U R E  4  Local	folding	of	nuclear	
localization	signal	residues	in	R33W	
mutant.	(A)	Snapshots	extracted	from	
molecular	dynamics	(MD)	simulation	of	
wild‐type	angiogenin	(ANG)	(a	and	b)	
showing its open conformation and loose 
packing of 31RRR33	nuclear	localization	
signal residues as compared to the closed 
and tight packing of 31RRW33	residues	(c	
and	d)	observed	during	MD	simulations.	
(B)	Computed	solvent‐accessible	surface	
area	(SASA)	from	MD	simulations	of	
nuclear	localization	signal	residues	
31RRR33 or 31RRW33	for	wild‐type	ANG	
and	R33W	mutant,	respectively.	Reduced	
SASA	in	R33W	mutant	indicates	that	it	
may lose its nuclear translocation ability 
as	compared	to	wild‐type.	SASA	of	R31,	
R32,	and	R33/W33	are	shown	in	black,	
red,	and	blue,	respectively
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origin	(Zou	et	al.,	2011).	According	to	previously	reported	molecular	
simulation	results	of	the	V103I	variant	structure,	a	hydrogen	bond	
interaction network connecting from I103 to H114 was proposed 
(Padhi	et	al.,	2012).	Enzyme	activity	assays	showed	that	the	V103I	
mutant	retains	54.1%	of	enzymatic	activity	toward	tRNA	(Bradshaw	
et	al.,	2017).	Observing	SASA	values	of	the	V103I	mutant,	it	is	pre‐
dicted	that	the	nuclear	translocation	activity	is	also	impaired	(Padhi	
et	al.,	2012).
4.3 | R33W mutation
The	R33W	missense	 variant,	 located	 in	 the	 nuclear	 translocation	
signal	of	the	mature	protein,	has	not	been	identified	in	ALS	patients	
before. To understand the role of the mutation in disease manifes‐
tation,	 a	 computational	 and	 functional	 analysis	of	 the	R33W	mu‐
tant	was	performed.	Our	MD	simulations	showed	that	 the	R33W	
mutation results in partial loss of ribonucleolytic activity and im‐
paired nuclear translocation activity. The ribonucleolytic assay and 
nuclear	 translocation	 assay	of	 the	R33W	ANG	protein	 confirmed	
the	MD	results.	According	to	the	ribonucleolytic	activity	assay,	the	
R33W	mutant	 protein	 retained	 57.4%	 of	 catalytic	 activity	 of	 the	
wild‐type	 protein.	 Previous	 studies	 described	 that	 the	 reported	
disease‐causing	 ANG	 mutations—except	 variant	 R121C—show	 a	
reduced level of catalytic activity in a range of 0%–95% compared 
with	the	wild‐type	ANG	(Bradshaw	et	al.,	2017;	Padhi	et	al.,	2014;	
Wu	et	al.,	2007).
Since	the	R33W	variant	affects	the	key	amino	acid	of	the	nuclear	
localization	signal	of	ANG,	this	function	of	the	mutant	protein	is	also	
compromised. Our nuclear translocation assay showed that the al‐
teration	of	Arg33	 to	Trp33	 in	ANG	 significantly	 reduced	 its	 entry	
into	the	nucleus.	Amino	acids	29IMRRRGL35 are part of the nuclear 
localization	signal	and	are	involved	in	nuclear	translocation	of	ANG.	
The arginine residues 31RRR33 are critical in governing the nuclear 
translocation	of	ANG:	R33	 is	 essential	 and	 residues	 31RR32 modu‐
late	 the	 process.	Moroianu	 and	Riordan	 (1994)	 described	 that	 the	
R33A	mutant	ANG	protein	 is	 not	 translocated	 to	 the	nucleus	 and	
lacks	angiogenic	activity	(Moroianu	&	Riordan,	1994).	Previous	stud‐
ies	showed	that	other	ALS‐associated	ANG	mutations	(S28N,	L35P,	
P112L,	K17I,	K17E,	Q12L)	also	result	 in	partial	or	complete	 loss	of	
nuclear translocation capability due to the changes in the folding of 
the 31RRR33	residues	and	subsequent	reduction	in	SASA	(Bradshaw	
et	al.,	2017;	Padhi	et	al.,	2014;	Thiyagarajan,	Ferguson,	Subramanian,	
&	Acharya,	2012;	Wu	et	al.,	2007).
Mature	ANG	contains	three	distinct	functional	sites:	a	receptor	
binding	region,	a	catalytic	triad	responsible,	which	is	for	ribonucle‐
ase	activity,	and	the	nuclear	localization	signal.	All	three	functional	
regions	are	needed	for	its	angiogenic	activity	(Moroianu	&	Riordan,	
1994).	Alterations	 in	 the	 structure	of	ANG	and	dynamics	 result	 in	
F I G U R E  5  Nuclear	translocation	of	wild‐type	(WT)	and	mutant	angiogenin	(ANG)	in	human	umbilical	vein	endothelial	cells	(HUVEC)	cells.	
HUVEC	cells	were	incubated	with	1	μg/ml	of	WT	ANG	or	mutant	ANG	for	30	min	and	subsequently	immunostained	for	ANG.	Nuclei	were	
stained	with	4′,6‐diamidino‐2‐phenylindole	(DAPI).	Images	show	the	representative	result	of	four	experiments.	(a)	WT	ANG	accumulates	
both	in	the	cytoplasm	and	nucleus	of	the	HUVEC	cells,	whereas	mutant	(R33W)	ANG	accumulated	predominantly	in	the	cytoplasm	of	the	
cells.	Individual	channels	as	well	as	merged	images	are	shown.	(b)	Nuclear	translocation	was	quantified	by	measuring	mean	signal	intensity	
levels	of	ANG	staining	in	nucleus	and	cytoplasm	of	cells	for	at	least	three	fields	of	views.	Quantification	of	nuclear	translocation	of	WT	and	
mutant	(R33W)	ANG	showed	a	significant	decrease	in	nuclear	staining	in	the	R33W‐treated	samples	(two‐tailed	Student's	t‐test,	p	<	0.0001).	
(c)	Mean	cellular	signal	intensity	levels	of	ANG	was	determined	for	at	least	three	fields	of	views,	which	showed	a	significant	difference	
between	the	intensity	of	staining	of	the	WT	and	mutant	protein	(two‐tailed	Student's	t‐test,	p	<	0.0001),	suggesting	a	difference	in	the	
cellular	internalization	of	the	protein
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loss	of	 ribonucleolytic	activity	and/or	nuclear	 translocation	ability,	
which	may	lead	to	ALS.
For	 the	R33W	variant,	 a	 strong	 correlation	 between	 the	 com‐
putational simulation predictions and functional analyses was ob‐
served.	 The	 evidence	 from	 clinical,	 computational,	 and	 functional	
analyses support the deleterious effect of the R33W variant de‐
tected in this study. Our findings also confirm the relevance of ANG 
mutations	 in	ALS	and	points	out	the	variability	among	populations	
of different ethnic origin. It underscores a substantial role of ANG 
variants	in	Hungarian	ALS	patients,	and	suggests	the	importance	of	
further large cohort studies.
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